CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

FierceBiotech
Original article

{"a":[{"_":"Corbus posts phase 1 obesity data for drug mechanism that defeated Novo, Sanofi","$":{"href":"/biotech/corbus-posts-phase-1-obesity-data-area-where-novo-and-sanofi-stumbled","hreflang":"en"}}]}

Phase 1positivePositive
AI Analysis

Summary

Corbus Pharmaceuticals reported positive phase 1b obesity trial data for its CB1 inverse agonist showing a potentially improved safety profile compared to prior competing approaches by Novo Nordisk and Sanofi, with plans to advance to phase 2.

Clinical Trial Data

Phase

1b

Outcome Details

Phase 1b data showed evidence of reduced neuropsychiatric side effects compared to competing mechanisms

Importance:6/10
Sentiment:
0.70
obesityCB1 inverse agonistphase 1bsafety profileneuropsychiatric side effects
Related Companies

Read the original article

Published by FierceBiotech on September 14, 2026 10:07 AM

Read Original